Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
EAST NORRITON, Pa., Oct. 25 /PRNewswire-FirstCall/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, announced today that surgeons at the University of Chicago have implanted its Neo-Urinary Conduit™ in the first patient as part of the ongoing clinical trial evaluating the Company's lead product candidate in bladder cancer patients requiring a urinary diversion following bladder removal. The patient is being treated at the University of Chicago Medical Center by the study's principal investigator, Gary D. Steinberg, M.D., professor of surgery and director, urologic oncology. The trial is also being conducted at The Johns Hopkins Hospital in Baltimore, Maryland.
"This implantation marks a significant milestone for bladder cancer patients and their physicians who are eager for a treatment alternative to the current standard of care," said Steven Nichtberger, M.D., president and chief executive officer of Tengion.
For many bladder cancer patients who have their cancerous bladders removed, the current standard of care is the surgical creation of a urinary diversion using a segment of the patient's own bowel tissue to carry urine from the kidneys to a plastic bag on the abdominal wall. Tengion's Neo-Urinary Conduit is built from a patient's own cells obtained from a fat biopsy. The product is designed to catalyze regeneration of native-like bladder tissue, eliminating the need to use bowel tissue as a replacement for the cancerous bladder. The Neo-Urinary Conduit is designed to avoid many of the complications associated with the use of bowel tissue. Complications most often associated with the current standard of care include bowel obstructions, bowel leakage, systemic absorption of urine via the bowel tissue, recurrent infections, stone formation, and mucus secretion in the urine.
The ongoing study, which initially